Application of peimisine in preparation of medicine for preventing and/or treating ulcerative colitis

A technology for ulcerative colitis and fritillary, applied in the field of medicine, can solve problems such as no anti-ulcerative colitis with fritillary, achieve excellent anti-ulcerative colitis activity, improve intestinal tissue pathological damage, prevent and intestinal tissue pathological damage

CN113288902APending Publication Date: 2021-08-24CHANGCHUN UNIV OF CHINESE MEDICINE +1
5 Cites 0 Cited by

Patent Information

Authority / Receiving Office
CN · China
Current Assignee / Owner
Publication Date
2021-08-24

Smart Images

  • Figure 1
    Figure 1
  • Figure 2
    Figure 2
  • Figure 3
    Figure 3
Patent Text Reader

Abstract

The invention discloses application of peimisine in preparation of medicines for preventing and / or treating ulcerative colitis, and relates to the field of medicines. Experiments prove that the peimisine has no significant influence on experimental mice: the experimental mice in a peimisine group have no death, no significant change in body weight, no obvious lesion in intestinal tissues, no obvious pathological symptoms in colon and cecum, and the peimisine has certain safety. The peimisine can reduce the weight loss rate of a mouse with the ulcerative colitis, can improve the fecal character and hemafecia condition of the mouse with the ulcerative colitis, can improve DAI of the mouse with the ulcerative colitis, and can effectively prevent and improve pathological damage of intestinal tissues of the mouse with the ulcerative colitis; and therefore, the peimisine has particularly excellent anti-ulcerative colitis activity and certain safety, and can obviously improve the ulcerative colitis symptom.
Need to check novelty before this filing date? Find Prior Art

Description

technical field

[0001] The invention relates to the technical field of medicine, in particular to the application of fritillaria in the preparation of medicines for preventing and / or treating ulcerative colitis. Background technique

[0002] Ulcerative colitis is a chronic nonspecific intestinal inflammatory disease whose etiology is not yet clear, characterized by continuous and diffuse inflammatory changes in the colorectal mucosa, and its lesions are mainly limited to the large intestinal mucosa and submucosa. The clinical manifestations are diarrhea, mucus pus and blood in the stool, and abdominal pain, and it is mostly a chronic course of repeated attacks.

[0003] At present, the clinical treatment of ulcerative colitis is based on the course of the disease, and aminosalicylic acid preparations (5-aminosalicylic acid or sulfasalazine, etc.), corticosteroids (prednisone or hydrocortisone, etc.) or Immunosuppressant (azathioprine or 6-mercaptopurine, etc.) to be treated...

Examples

Embodiment 1

[0049] Embodiment 1 Fritimin safety experiment

[0050] Eighteen healthy male C57BL / 6J mice with a body weight of about 20 g were randomly divided into 3 groups, 6 in each group, namely the control group, the fritillary (5 mg / kg) group and the fritillary (15 mg / kg) group. After a week of acclimatization. Prepare fritillaria with normal saline, and administer according to the body weight of the experimental mice every day. The fritillaria (5 mg / kg) group is given fritillaria by intraperitoneal injection of 5 mg / kg, and the fritillaria (15 mg / kg) group Intraperitoneal injection of 15 mg / kg of fritillaria was given, and 100 μL of normal saline was administered to the control group for 7 consecutive days. At the same time, the death, body weight, intestinal tissue, colon and cecum pathological conditions of the experimental mice in each group were recorded.

[0051] Experimental results such as figure 1 , figure 2 , image 3 and Figure 4 shown. The results showed that the ad...

Embodiment 2

[0052] The effect of embodiment 2 fritillaria on disease symptoms of ulcerative colitis mice

[0053] 50 healthy male C57BL / 6J mice with a body weight of about 20 g were randomly divided into 5 groups, 10 in each group, namely the control group, the model group, the positive drug group, the fritillary (5 mg / kg) group and the fritillary ( 15mg / kg) group. After adapting to the environment for one week, the mice were administered daily according to the body weight of the experimental mice. The control group drank normal water and injected 100 μL of normal saline intraperitoneally. , Fritimin (15mg / kg) group was administered with intraperitoneal injection of 15 mg / kg of fritillary, the model group was injected with 100 μL of normal saline, and the positive drug group was given 150 mg / kg of 5-aminosalicylic acid by intragastric administration, and continuously administered medicine for 7 days. After administration on the first day, 3% dextran sodium sulfate (Dextran Sulfate Sodiu...